Clinical practice guidelines for severe Alzheimer's disease
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: Although severe Alzheimer's disease (AD) represents a prevalent, serious, and costly public health problem, few practice guidelines exist to help physicians manage this disorder. Methods: A search of English language medical databases was performed from 1996 to the present for articles pertaining to the management of AD. The focus of this review was on studies that included patients with severe disease. Studies were assessed by considering the subjects, trial design, analysis, and results. Recommendations were based on the best available evidence. Results: Severe AD can be defined and diagnosed reliably by using measures of cognition, function, behavior, and global staging. Specific assessments would also include medical status, safety issues, and the health status of the caregiver. Disease‐specific management would include treatment with cholinesterase inhibitors and/or memantine. Treatment of neuropsychiatric symptoms begins with nonpharmacologic behavioral and environmental approaches. Severe agitation, aggression, and psychosis that are potentially dangerous to the patient, caregiver, and others in the environment can be treated with atypical antipsychotics, with consideration of their increased risk of cerebrovascular adverse events and mortality. All pharmacologic approaches require careful monitoring and regular periodic reassessments to determine whether ongoing treatment is necessary. Conclusions: Evidence‐based guidelines for the management of severe AD have the potential to improve the quality of life for the patient and their caregiver. More randomized controlled trials aimed specifically at this phase of illness are still urgently required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577 · cited 2×
“Subsequently, enthusiasm for reatment with vitamin E has waned even further because of large negative trial of vitamin E in mild cognitive impairent [91] as well as concerns that doses of vitamin E in xcess of 400 IU per day are associated with increased ortality [92].”
BackgroundA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 2×
“[7] Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA.”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 2×
“[91] Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R,”
BackgroundSchneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052827 · Cited by 959
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Agitated Behaviors in the Elderly: I. A Conceptual Review
Cohen‐Mansfield, J., & Billig, N. (1986) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1986.tb04302.x · Cited by 717 · cited 1×
“Other useful easily administered cales include Cornell Depression Rating Scale [49] and the ohen-Mansfield Agitation Inventory [50].”
MethodDeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · cited 1×
“[71] DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al.”
BackgroundA Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb02407.x · Cited by 650
Cohen-Mansfield, J. (2001) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00005 · Cited by 593
Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591
The importance of neuritic plaques and tangles to the development and evolution of AD
Tiraboschi, P., Hansen, L. A., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129697.01779.0a · Cited by 477 · cited 2×
“[64] Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J.”
BackgroundBrodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., Lee, E., Lyons, B., & Grossman, F. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0205 · Cited by 464
Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422
A Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer's Disease
Singer, C., Tractenberg, R. E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., & Thal, L. J. (2003) · Sleep · doi:10.1093/sleep/26.7.893 · Cited by 407
Gill, S. S., Rochon, P. A., Herrmann, N., Lee, P. E., Sykora, K., Gunraj, N., Normand, S.-L. T., Gurwitz, J. H., Marras, C., Wodchis, W. P., et al. (2005) · BMJ · doi:10.1136/bmj.38330.470486.8f · Cited by 402
Self-citationLyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398
Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
Teri, L., Logsdon, R. G., Peskind, E., Raskind, M., Weiner, M. F., Tractenberg, R. E., Foster, N. L., Schneider, L. S., Sano, M., Whitehouse, P., et al. (2000) · Neurology · doi:10.1212/wnl.55.9.1271 · Cited by 330
Pollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 327
Incontinence and Troublesome Behaviors Predict Institutionalization in Dementia
O'Donnell, B. F., Drachman, D. A., Barnes, H. J., Peterson, K. E., Swearer, J. M., & Lew, R. A. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500108 · Cited by 297 · cited 1×
“[55] O’Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer”
BackgroundPsychiatric Symptoms Vary With the Severity of Dementia in Probable Alzheimer's Disease
Lopez, O. L., Becker, J. T., Sweet, R. A., Klunk, W., Kaufer, D. I., Saxton, J., Habeych, M., & DeKosky, S. T. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.3.346 · Cited by 286 · cited 3×
“berrant motor behaviors such as restlessness, pacing, and andering are also common and particularly prevalent and isturbing in residents of long-term care who remain amulatory [1,34,35].”
BackgroundLanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900705 · Cited by 191 · cited 2×
“[68] Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N.”
BackgroundSelf-citationSnowden, M., Sato, K., & Roy‐Byrne, P. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51417.x · Cited by 171
Opie, J., Rosewarne, R., & O'Connor, D. W. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.1999.00652.x · Cited by 166
Olin, J. T., Fox, L. S., Pawluczyk, S., Taggart, N. A., & Schneider, L. S. (2001) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00008 · Cited by 163
The staging and assessment of moderate to severe Alzheimer disease
Feldman, H. H., & Woodward, M. (2005) · Neurology · doi:10.1212/wnl.65.6_suppl_3.s10 · Cited by 105 · cited 1×
“Cognitive assessment It is widely recognized the MMSE suffers from a floor ffect and is relatively insensitive to change in severe AD hen scores drop below 10 [15], and it can no longer be sed when language is severely affected [1].”
BackgroundTrinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Management of behavioral problems in Alzheimer's disease
Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., & Lyketsos, C. (2010) · International Psychogeriatrics · doi:10.1017/s1041610209991505 · Cited by 361
Self-citationAshton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0649-3 · Cited by 172
Kim, S.-Y., Yoo, E.-Y., Jung, M.-Y., Park, S.-H., & Park, J.-H. (2012) · NeuroRehabilitation: An International, Interdisciplinary Journal · doi:10.3233/nre-2012-0779 · Cited by 70
Bédard, A., Landreville, P., Voyer, P., Verreault, R., & Vézina, J. (2011) · Aging & Mental Health · doi:10.1080/13607863.2011.569480 · Cited by 43
Metadata
- Authors
- Herrmann, N., Gauthier, S., & Lysy, P. G.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2007-09-18
- Volume
- 3
- Issue
- 4
- Pages
- 385-397
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2073188741
- Cited by
- 65
- References
- 32
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.